Isradipine
As of the edition of 20 October 2026, Isradipine is a small molecule: marketed, first approved in 1990 (US); acts on CACNA1C, CACNA1D and CACNA1F and 1 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1990
- Kind
- Small molecule
- Brand name
- Dynacirc
- First approved
- 20 December 1990 (US)
- Approvals on record
- 5 in 2 regions
- Holder of the most recent approval
- GSK; 3 holders in all
- Registered trials
- 7, 1 stopped early
- Disease areas
- Mental health; Chemically induced; Nervous system; Injuries
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Isradipine.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 3 | 2 | 0 | 1 |
| All trials | 7 |